Marvisi, Chiara
 Distribuzione geografica
Continente #
AS - Asia 3.239
NA - Nord America 3.084
EU - Europa 1.803
SA - Sud America 427
AF - Africa 67
OC - Oceania 14
Totale 8.634
Nazione #
US - Stati Uniti d'America 2.998
SG - Singapore 1.074
CN - Cina 945
IT - Italia 625
HK - Hong Kong 348
BR - Brasile 340
VN - Vietnam 305
DE - Germania 217
GB - Regno Unito 210
FI - Finlandia 193
BD - Bangladesh 153
KR - Corea 153
RU - Federazione Russa 120
SE - Svezia 100
FR - Francia 85
NL - Olanda 50
CA - Canada 44
IN - India 44
ID - Indonesia 42
IE - Irlanda 38
AR - Argentina 34
AT - Austria 30
MX - Messico 29
IQ - Iraq 28
JP - Giappone 27
LT - Lituania 22
MA - Marocco 20
BG - Bulgaria 19
PL - Polonia 19
TR - Turchia 19
UA - Ucraina 14
AU - Australia 13
CL - Cile 13
PK - Pakistan 13
KW - Kuwait 12
PT - Portogallo 12
ZA - Sudafrica 12
EC - Ecuador 10
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
ES - Italia 9
SA - Arabia Saudita 9
PE - Perù 8
UZ - Uzbekistan 8
CZ - Repubblica Ceca 7
PH - Filippine 7
TW - Taiwan 7
IL - Israele 6
KE - Kenya 6
VE - Venezuela 6
AZ - Azerbaigian 5
CO - Colombia 5
GR - Grecia 5
AL - Albania 4
EG - Egitto 4
LB - Libano 4
MY - Malesia 4
PY - Paraguay 4
TH - Thailandia 4
TN - Tunisia 4
UY - Uruguay 4
BE - Belgio 3
CH - Svizzera 3
CR - Costa Rica 3
KG - Kirghizistan 3
LV - Lettonia 3
MT - Malta 3
RS - Serbia 3
AM - Armenia 2
BS - Bahamas 2
ET - Etiopia 2
GY - Guiana 2
KZ - Kazakistan 2
SN - Senegal 2
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BJ - Benin 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
HN - Honduras 1
IM - Isola di Man 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
KY - Cayman, isole 1
LI - Liechtenstein 1
MD - Moldavia 1
MG - Madagascar 1
MU - Mauritius 1
MW - Malawi 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
Totale 8.627
Città #
Santa Clara 677
Singapore 670
Hefei 486
Ashburn 358
Hong Kong 344
San Jose 329
Helsinki 168
Seoul 151
London 130
Munich 129
Beijing 118
Ho Chi Minh City 103
Chandler 101
Los Angeles 86
Milan 85
Council Bluffs 83
The Dalles 83
Fairfield 81
Hanoi 67
Nyköping 64
Dallas 62
New York 56
Chicago 55
Moscow 50
Lauterbourg 46
Dublin 37
Buffalo 36
Bologna 35
Rome 35
Jakarta 34
Seattle 31
São Paulo 31
Shanghai 29
Houston 27
Kent 27
Cambridge 26
Salt Lake City 26
Boardman 25
Nuremberg 25
Wilmington 24
San Diego 23
Woodbridge 23
Frankfurt am Main 22
Atlanta 18
Modena 18
Haiphong 17
Naples 17
Orem 17
Portsmouth 17
Redondo Beach 17
Rio de Janeiro 17
Tokyo 17
Amsterdam 15
Princeton 15
Bremen 13
Lappeenranta 13
Toronto 13
Vienna 13
Florence 12
Kuwait City 12
Tampa 12
Brooklyn 11
Da Nang 11
Elk Grove Village 11
Montreal 11
Sofia 11
Turin 11
Denver 10
Mexico City 10
Reggio Emilia 10
Ankara 9
Manchester 9
Melbourne 9
San Francisco 9
Turku 9
Ann Arbor 8
Chennai 8
Columbus 8
Des Moines 8
Ksawerów 8
Padova 8
Santiago 8
Tashkent 8
Warsaw 8
Baghdad 7
Brasília 7
Campinas 7
Casablanca 7
Curitiba 7
Lancaster 7
Mumbai 7
Palermo 7
Biên Hòa 6
Brescia 6
Charlotte 6
Dearborn 6
Düsseldorf 6
Fortaleza 6
Guangzhou 6
Las Vegas 6
Totale 5.688
Nome #
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 331
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 306
EULAR guidelines on ANCA-associated vasculitis in the real life 269
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 231
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 216
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 207
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status 202
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 198
Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center 197
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 196
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 189
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 186
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 182
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 180
EVALUATION OF INTERNAL CONSISTENCY, FEASIBILITY, AND RELIABILITY OF THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE: PRELIMINARY RESULTS FROM A MULTICENTER STUDY ON A LARGE COHORT OF ITALIAN PATIENTS 179
EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 174
The role of sacro-iliac joint magnetic resonance imaging in the diagnosis of axial spondyloarthritis: focus on differential diagnosis in women 169
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 167
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis 167
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 164
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 160
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 159
117. PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG– STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS 158
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study 157
354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 155
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 153
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways 149
Development of the Takayasu Arteritis Integrated Disease Activity Index 149
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 148
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 147
Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients 145
What to Know About Biopsy Sampling and Pathology in Vasculitis? 142
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 141
The management of large vessel vasculitides 140
Eosinophilic giant cell arteritis: A different subset of disease? 138
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 134
Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases 133
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 132
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 132
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study 132
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 130
Aortitis and periaortitis: The puzzling spectrum of inflammatory aortic diseases 125
Pros and cons of TNF inhibitors and tocilizumab in the treatment of large-vessel vasculitis 125
The Role of PET in the Diagnosis and Disease Activity Assessment in Large Vessel Vasculitis 123
Comment on: Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study. Reply 118
Comparing treatment options for large vessel vasculitis 114
Reply 113
Systemic vasculitis: one year in review 2024 103
Vasculitis, fibromuscular dysplasia or hereditary aneurysms? 102
Manifestations of Skull Base IgG4‐Related Disease: A Multi‐Institutional Study 96
Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease 91
PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS 91
Reply to Comment on: Vasculitis, fibromuscular dysplasia or hereditary aneurysms? by Marvisi et al 89
The geographic and clinical clusters of Behçet’s syndrome 86
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors 72
Hypereosinophilia and eosinophilic arterial aneurysm: not only eosinophilic granulomatosis with polyangiitis 67
The influence of baseline aortitis on aortic dilation risk in GCA: a multicentre imaging study 16
Is immunotherapy safe and effective in patients with VEXAS syndrome? 15
Exploring total inflammatory vascular volume as a diagnostic and prognostic biomarker in giant cell arteritis 14
Utilità clinica dell'imaging nell'arterite gigantocellulare 1
Totale 8.705
Categoria #
all - tutte 35.902
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.902


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 0 0 0 0 0 0 16
2021/2022258 12 24 19 8 11 23 10 13 23 19 46 50
2022/2023483 35 47 28 20 69 51 33 52 60 22 38 28
2023/2024499 14 28 13 62 47 59 65 54 17 33 55 52
2024/20252.700 45 21 86 168 508 442 275 88 321 140 329 277
2025/20264.616 403 255 435 517 532 248 599 192 494 363 373 205
Totale 8.705